Alvaro Moreno-Aspitia

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer
    Alvaro Moreno-Aspitia
    Mayo Clinic, Jacksonville, FL 32224, USA
    Future Oncol 1:755-62. 2005
  2. doi request reprint Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Cancer 119:2675-82. 2013
  3. doi request reprint Neoadjuvant therapy in early-stage breast cancer
    Alvaro Moreno-Aspitia
    Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Crit Rev Oncol Hematol 82:187-99. 2012
  4. doi request reprint Clinical overview of sorafenib in breast cancer
    Alvaro Moreno-Aspitia
    Mayo College of Medicine, Multidisciplinary Breast Clinic, Mayo Clinic Florida, FL, USA
    Future Oncol 6:655-63. 2010
  5. doi request reprint Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends
    Alvaro Moreno-Aspitia
    College of Medicine, Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Clin Ther 31:1619-40. 2009
  6. ncbi request reprint The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard?
    A Moreno
    Mayo Graduate School of Medicine and Division of Hematology Oncology, The Mayo Clinic, Jacksonville, Florida 32224, USA
    Oncologist 5:238-49. 2000
  7. pmc Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology, Mayo Clinic and Mayo Foundation, Jacksonville, FL 32224, USA
    J Clin Oncol 27:11-5. 2009
  8. ncbi request reprint Assessment of platelet numbers and morphology in the peripheral blood smear
    Alvaro Moreno
    Division of Hematology Oncology and Internal Medicine, Mayo Medical School, Jacksonville, Florida, USA
    Clin Lab Med 22:193-213, vii. 2002
  9. pmc Treatment options for breast cancer resistant to anthracycline and taxane
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology Cancer Center Breast Clinic, Mayo Clinic, Jacksonville, FL 32224, USA
    Mayo Clin Proc 84:533-45. 2009
  10. pmc Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
    Edith A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 29:4491-7. 2011

Detail Information

Publications21

  1. ncbi request reprint Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer
    Alvaro Moreno-Aspitia
    Mayo Clinic, Jacksonville, FL 32224, USA
    Future Oncol 1:755-62. 2005
    ....
  2. doi request reprint Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Cancer 119:2675-82. 2013
    ..In this study, the authors evaluated levels of sHER2 during treatment and at the time of disease recurrence in the adjuvant North Central Cancer Treatment Group N9831 clinical trial...
  3. doi request reprint Neoadjuvant therapy in early-stage breast cancer
    Alvaro Moreno-Aspitia
    Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Crit Rev Oncol Hematol 82:187-99. 2012
    ..It remains to be seen whether novel cytotoxic agents used in the neoadjuvant setting will improve pathologic clinical response rates and ultimately improve long-term outcome in women with early-stage breast cancer...
  4. doi request reprint Clinical overview of sorafenib in breast cancer
    Alvaro Moreno-Aspitia
    Mayo College of Medicine, Multidisciplinary Breast Clinic, Mayo Clinic Florida, FL, USA
    Future Oncol 6:655-63. 2010
    ..This article reviews previous experiences and current and future development strategies of sorafenib in breast cancer...
  5. doi request reprint Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends
    Alvaro Moreno-Aspitia
    College of Medicine, Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Clin Ther 31:1619-40. 2009
    ..Resistance to the commonly used chemotherapies anthracyclines and taxanes, as well as the approval of new pharmacologic options for treating BC, present important clinical, cost-effectiveness, and societal challenges...
  6. ncbi request reprint The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard?
    A Moreno
    Mayo Graduate School of Medicine and Division of Hematology Oncology, The Mayo Clinic, Jacksonville, Florida 32224, USA
    Oncologist 5:238-49. 2000
    ..S. are aware of the different dose schedules of prednisone in the published CHOP programs...
  7. pmc Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology, Mayo Clinic and Mayo Foundation, Jacksonville, FL 32224, USA
    J Clin Oncol 27:11-5. 2009
    ..We conducted a cooperative group phase II study to assess antitumor activity and toxicity of sorafenib in patients with metastatic breast cancer (MBC) who had received prior treatment for their disease...
  8. ncbi request reprint Assessment of platelet numbers and morphology in the peripheral blood smear
    Alvaro Moreno
    Division of Hematology Oncology and Internal Medicine, Mayo Medical School, Jacksonville, Florida, USA
    Clin Lab Med 22:193-213, vii. 2002
    ..This article focuses on disorders affecting the number or morphology of platelets as assessed by evaluation of a peripheral blood smear and also outlines some of their important clinical findings...
  9. pmc Treatment options for breast cancer resistant to anthracycline and taxane
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology Cancer Center Breast Clinic, Mayo Clinic, Jacksonville, FL 32224, USA
    Mayo Clin Proc 84:533-45. 2009
    ..Published sources for this review were found by searching PubMed (https://www.ncbi.nlm.nih.gov/pubmed) and congress Web sites...
  10. pmc Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer
    Edith A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 29:4491-7. 2011
    ....
  11. doi request reprint Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
    Edith A Perez
    Division of Hematology and Oncology, College of Medicien, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 121:261-71. 2010
    ....
  12. doi request reprint Adjuvant therapy of triple negative breast cancer
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 120:285-91. 2010
    ....
  13. ncbi request reprint Issues and controversies in the treatment of HER2 positive metastatic breast cancer
    Surabhi Amar
    Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 109:1-7. 2008
    ..Ongoing trials designed to maximize the therapeutic ratio of these agents, are also discussed...
  14. doi request reprint Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437
    Monica M Reinholz
    Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55906, USA
    Clin Cancer Res 17:7183-93. 2011
    ....
  15. pmc RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
    Alvaro Moreno-Aspitia
    Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA
    Breast Cancer Res Treat 138:427-35. 2013
    ..The addition of lapatinib to paclitaxel and trastuzumab following AC does not add cardiac toxicity. Lapatinib dose of 750 mg/day in combination with standard chemotherapy plus trastuzumab has acceptable overall tolerability...
  16. pmc Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831
    Jennifer A Crozier
    Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida 32224, USA
    Cancer 119:2447-54. 2013
    ..The authors hypothesized that there would be a correlation between BMI and clinical outcome in patients with early stage, human epidermal receptor 2 (HER2)-positive breast cancer enrolled in the N9831 adjuvant trial...
  17. ncbi request reprint North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer
    Alvaro Moreno-Aspitia
    Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    Clin Breast Cancer 6:361-4. 2005
  18. ncbi request reprint Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3400-7. 2004
    ..Of the 14 evaluable patients, all have had neurologic improvement or stabilization. Other features have improved substantially. PBSCT for POEMS syndrome is effective therapy but may also be associated with significant morbidity...
  19. ncbi request reprint Audit of nutrition support for hematopoietic stem cell transplantation at a single institution
    James S Scolapio
    Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Jacksonville, Fla 32224, USA
    Mayo Clin Proc 77:654-9. 2002
    ..To analyze experience with total parenteral nutrition (TPN) for hematopoietic stem cell transplantation (HSCT) at our institution compared with reports in the literature...
  20. doi request reprint Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients
    Abba C Zubair
    Transfusion Medicine, Department of Pathology and Division of Hematology Oncology, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
    Transfusion 48:1106-14. 2008
    ..It is also challenging to predict if the collected cells will be enough for one or two transplants...
  21. ncbi request reprint Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial
    Alvaro Moreno-Aspitia
    Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA
    Cancer 107:767-72. 2006
    ..Thalidomide has shown promise for the treatment of patients with myelodysplastic syndrome. The current prospective multicenter study examined the efficacy and toxicity of thalidomide in adult patients with myelodysplastic syndrome...